138 related articles for article (PubMed ID: 12044553)
21. Efficacy of inactivation of viral contaminants in hyperimmune horse plasma against botulinum toxin by low pH alone and combined with pepsin digestion.
Torgeman A; Mador N; Dorozko M; Lifshitz A; Eschar N; White MD; Wolf DG; Epstein E
Biologicals; 2017 Jul; 48():24-27. PubMed ID: 28633975
[TBL] [Abstract][Full Text] [Related]
22. [Nanofiltration in production of Beriplex P/N: increasing the capacity of virus elimination while maintaining product quality].
Römisch J; Gröner A; Bernhardt D; Diehl KH; Hein B; List W; Müller HG; Nowak T; Ronneberger H; Schüler E; Weimer T; Hilfenhaus J
Beitr Infusionsther Transfusionsmed; 1996; 33():220-4. PubMed ID: 8974698
[TBL] [Abstract][Full Text] [Related]
23. Effect of gamma irradiation on human cortical bone transplants contaminated with enveloped and non-enveloped viruses.
Pruss A; Kao M; Gohs U; Koscielny J; von Versen R; Pauli G
Biologicals; 2002 Jun; 30(2):125-33. PubMed ID: 12127314
[TBL] [Abstract][Full Text] [Related]
24. Low pH, caprylate incubation as a second viral inactivation step in the manufacture of albumin. Parametric and validation studies.
Johnston A; Uren E; Johnstone D; Wu J
Biologicals; 2003 Sep; 31(3):213-21. PubMed ID: 12935811
[TBL] [Abstract][Full Text] [Related]
25. Inactivation of HIV, HBV, HCV related viruses and other viruses in human plasma derivatives by pasteurisation.
Nowak T; Niedrig M; Bernhardt D; Hilfenhaus J
Dev Biol Stand; 1993; 81():169-76. PubMed ID: 8174799
[TBL] [Abstract][Full Text] [Related]
26. Pathogen Safety of a New Intravenous Immune Globulin 10% Liquid.
Radomski KU; Lattner G; Schmidt T; Römisch J
BioDrugs; 2017 Apr; 31(2):125-134. PubMed ID: 28236170
[TBL] [Abstract][Full Text] [Related]
27. New methods for inactivation of lipid-enveloped and non-enveloped viruses.
Miekka SI; Busby TF; Reid B; Pollock R; Ralston A; Drohan WN
Haemophilia; 1998 Jul; 4(4):402-8. PubMed ID: 9873761
[TBL] [Abstract][Full Text] [Related]
28. Removal of viral contaminants by monoclonal antibody purification of plasma proteins.
Schreiber AB; Hrinda ME; Newman J; Tarr GC; D'Alisa R; Curry WM
Curr Stud Hematol Blood Transfus; 1989; (56):146-53. PubMed ID: 2491983
[TBL] [Abstract][Full Text] [Related]
29. Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment in plasma derived intermediates.
Korneyeva M; Hotta J; Lebing W; Rosenthal RS; Franks L; Petteway SR
Biologicals; 2002 Jun; 30(2):153-62. PubMed ID: 12127317
[TBL] [Abstract][Full Text] [Related]
30. "In vitro" and in animal model studies on a double virus-inactivated factor VIII concentrate.
Arrighi S; Rossi R; Borri MG; Lesnikov V; Lesnikova M; Franco E; Divizia M; De Santis ME; Bucci E
Thromb Haemost; 1995 Sep; 74(3):868-73. PubMed ID: 8571312
[TBL] [Abstract][Full Text] [Related]
31. Effect of terminal (dry) heat treatment on non-enveloped viruses in coagulation factor concentrates.
Hart HF; Hart WG; Crossley J; Perrie AM; Wood DJ; John A; McOmish F
Vox Sang; 1994; 67(4):345-50. PubMed ID: 7701804
[TBL] [Abstract][Full Text] [Related]
32. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
[TBL] [Abstract][Full Text] [Related]
33. Pasteurized, monoclonal antibody factor VIII concentrate: establishing a new standard for purity and viral safety of plasma-derived concentrates.
Goldsmith JC
Blood Coagul Fibrinolysis; 2000 Mar; 11(2):203-15. PubMed ID: 10759015
[TBL] [Abstract][Full Text] [Related]
34. Viral safety of C1-inhibitor NF.
Terpstra FG; Kleijn M; Koenderman AH; Over J; van Engelenburg FA; Schuitemaker H; van 't Wout AB
Biologicals; 2007 Jun; 35(3):173-81. PubMed ID: 17071103
[TBL] [Abstract][Full Text] [Related]
35. Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus- inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections.
Schmitt HJ; Knuf M; Ortiz E; Sänger R; Uwamwezi MC; Kaufhold A
J Pediatr; 2000 Sep; 137(3):304-12. PubMed ID: 10969252
[TBL] [Abstract][Full Text] [Related]
36. [Validation of the virus inactivation capacity of a procedure of human plasma albumin purification by chromatography].
Stoltz JF; Geschier C; Rivat C; Sertillanges P; Grandgeorges M; Liautaud J; Regnault V; Dumont L
Ann Pharm Fr; 1993; 51(2):78-93. PubMed ID: 8250488
[TBL] [Abstract][Full Text] [Related]
37. Nanofiltration of plasma-derived biopharmaceutical products.
Burnouf T; Radosevich M
Haemophilia; 2003 Jan; 9(1):24-37. PubMed ID: 12558776
[TBL] [Abstract][Full Text] [Related]
38. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
[TBL] [Abstract][Full Text] [Related]
39. Immunoglobulin G elution in protein A chromatography employing the method of chromatofocusing for reducing the co-elution of impurities.
Pinto ND; Uplekar SD; Moreira AR; Rao G; Frey DD
Biotechnol Bioeng; 2017 Jan; 114(1):154-162. PubMed ID: 27425244
[TBL] [Abstract][Full Text] [Related]
40. Induction of virus-neutralizing antibodies by bacteria expressing the C3 poliovirus epitope in the periplasm. The route of immunization influences the isotypic distribution and the biologic activity of the antipoliovirus antibodies.
LeClerc C; Martineau P; Van der Werf S; Deriaud E; Duplay P; Hofnung M
J Immunol; 1990 Apr; 144(8):3174-82. PubMed ID: 2157762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
